These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9128797)

  • 1. Recombinant human erythropoietin for anaemia in nephrotic syndrome with thalassemia.
    Ng YY; Liu SM; Chadban S; Lan HY; Huang TP
    Clin Nephrol; 1997 Apr; 47(4):273-4. PubMed ID: 9128797
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropoietin.
    Bayés B; Serra A; Juncà J; Lauzurica R
    Nephrol Dial Transplant; 1998 Jul; 13(7):1894-5. PubMed ID: 9681764
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant erythropoietin for treatment of anaemia in HIV-infected children.
    Caselli D; Maccabruni A; Zuccotti GV; Riva E; Fundaro C; Portelli V; Galli L; Zizzadoro P; Gabiano C; Forni GL
    AIDS; 1996 Jul; 10(8):929-31. PubMed ID: 8828757
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?
    Osterborg A
    Med Oncol; 1998 Aug; 15 Suppl 1():S47-9. PubMed ID: 9785337
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy.
    Breymann C; Fibach E; Visca E; Huettner C; Huch A; Huch R
    J Matern Fetal Med; 1999; 8(1):1-7. PubMed ID: 10052837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction.
    Ishimitsu T; Ono H; Sugiyama M; Asakawa H; Oka K; Numabe A; Abe M; Matsuoka H; Yagi S
    Nephron; 1996; 74(3):607-10. PubMed ID: 8938689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin.
    Cazzola M
    Med Oncol; 2000 Nov; 17 Suppl 1():S11-6. PubMed ID: 11188780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Response to recombinant human erythropoietin of anemia secondary to pressure ulcers in a patient with multiple sclerosis].
    Sánchez Marín B; Grasa JM; García Erce JA; Pérez Lungmus G
    Rev Neurol; 2001 Nov 16-30; 33(10):997-8. PubMed ID: 11785020
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma.
    San Miguel JF; García-Sanz R
    Med Oncol; 1998 Aug; 15 Suppl 1():S29-34. PubMed ID: 9785334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neonatal anaemia secondary to rhesus incompatibility treated by recombinant erythropoietin].
    Kayemba-Kay's S; Christin P; Yahouanc-Lapalle H; Oriot D
    Arch Pediatr; 2004 Jul; 11(7):868-9. PubMed ID: 15234390
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
    Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
    Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of anaemia in chronic heart failure--optimal approach still unclear.
    Murphy NF; McDonald K
    Eur Heart J; 2007 Sep; 28(18):2185-7. PubMed ID: 17704094
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of recombinant human erythropoietin in anemia of malignancy.
    Cazzola M
    Med Oncol; 1998 Aug; 15 Suppl 1():S1-2. PubMed ID: 9785329
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
    Hasselbalch HC; Clausen NT; Jensen BA
    Am J Hematol; 2002 Jun; 70(2):92-9. PubMed ID: 12111781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European best practice guidelines 1-4: evaluating anaemia and initiating treatment.
    Valderrábano F; Hörl WH; Jacobs C; Macdougall IC; Parrondo I; Cremers S; Abraham IL
    Nephrol Dial Transplant; 2000; 15 Suppl 4():8-14. PubMed ID: 11052144
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of chronic skin ulcers in individuals with anemia of chronic disease using recombinant human erythropoietin (EPO): a review of four cases.
    Keast DH; Fraser C
    Ostomy Wound Manage; 2004 Oct; 50(10):64-70. PubMed ID: 15509883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of human recombinant erythropoietin in children with cancer].
    Guyot D; Margueritte G
    Arch Pediatr; 2005 Sep; 12(9):1376-82. PubMed ID: 16084072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anaemia, cardiac failure and erythropoietin].
    Cohen Solal A; Beauvais F
    Arch Mal Coeur Vaiss; 2005 Oct; 98(10):997-1001. PubMed ID: 16294546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothyroidism and resistance to human recombinant erythropoietin.
    Touam M; Guéry B; Goupy C; Menoyo V; Drüeke T
    Nephrol Dial Transplant; 2004 Apr; 19(4):1020-1. PubMed ID: 15031379
    [No Abstract]   [Full Text] [Related]  

  • 20. Erythropoietin therapy: need for rationality and active surveillance.
    Cazzola M
    Haematologica; 2003 Jun; 88(6):601-5. PubMed ID: 12801832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.